EA 230Alternative Names: EA-230; Peptide 46; Peptide EA 230
Latest Information Update: 27 Jul 2016
At a glance
- Originator Exponential Biotherapies
- Class Anti-inflammatories; Antiseptics; Peptides
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Renal failure
Most Recent Events
- 17 Jul 2016 Phase-II/III clinical trials in Renal failure (Prevention) in Netherlands (IV) (EudraCT2014-002481-78)
- 07 Oct 2014 Exponential Biotherapies initiates enrolment in a phase I trial for Renal failure (Prevention, In volunteers) in Netherlands (EudraCT2014-002481-78)